{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:45:46Z","timestamp":1785854746996,"version":"3.56.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1097\/01.mbc.0000164427.13417.06","type":"journal-article","created":{"date-parts":[[2005,3,28]],"date-time":"2005-03-28T04:01:36Z","timestamp":1111982496000},"page":"187-192","source":"Crossref","is-referenced-by-count":1,"title":["Study of human von Willebrand factor immunogenicity in pigs with severe von Willebrand disease"],"prefix":"10.1097","volume":"16","author":[{"given":"Annick","family":"Sauger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Chtourou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Samor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Bonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Roussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Mazurier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/beha.2001.0143","article-title":"Management of inherited von Willebrand disease","volume":"14","author":"Mannucci","year":"2001","journal-title":"Best Practice Res Clin Haematol"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1046\/j.1365-2516.2000.00059.x","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years","volume":"6","author":"Mannucci","year":"2000","journal-title":"Haemophilia"},{"key":"R4-5-20210203","first-page":"193","article-title":"Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease","volume":"62","author":"Rodeghiero","year":"1992","journal-title":"Vox Sang"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial","volume":"79","author":"Mannucci","year":"1992","journal-title":"Blood"},{"key":"R6-5-20210203","first-page":"173","article-title":"The use of intermediate and high purity factor VIII products in the treatment of von Willebrand Disease","volume":"71","author":"Hanna","year":"1994","journal-title":"Thromb Haemost"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.1992.tb01159.x","article-title":"Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate","volume":"62","author":"Burnouf-Radosevich","year":"1992","journal-title":"Vox Sang"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2141.1992.tb08903.x","article-title":"Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity","volume":"80","author":"Goudemand","year":"1992","journal-title":"Br J Haemat"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.1991.tb00918.x","article-title":"In vitro evaluation of a very-high purity solvent\/detergent treated von Willebrand factor concentrate","volume":"61","author":"Mazurier","year":"1991","journal-title":"Vox Sang"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","article-title":"Clinical management of patients with von Willebrand's disease with a VHP VWF concentrate: the French experience","volume":"4","author":"Goudemand","year":"1998","journal-title":"Haemophilia"},{"key":"R11-5-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.0042-9007.2004.00398.x","article-title":"In vitro study of a triple-secured von Willebrand factor concentrate","volume":"86","author":"Mazurier","year":"2004","journal-title":"Vox Sang"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","article-title":"Immunogenicity of therapeutic proteins: clinical implications, future prospects","volume":"24","author":"Schellekens","year":"2002","journal-title":"Clin Ther"},{"key":"R13-5-20210203","first-page":"348","article-title":"Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor","volume":"125","author":"Bergamaschini","year":"1995","journal-title":"J Lab Clin Med"},{"key":"R14-5-20210203","first-page":"187","article-title":"Interaction of platelets with endothelium in normal and von Willebrand pigs","author":"Fuster","year":"1978"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00001721-199806000-00009","article-title":"Effects of human recombinant, plasma derived and porcine von Willebrand factor in pigs with severe von Willebrand disease","volume":"9","author":"Roussi","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0049-3848(75)90074-2","article-title":"Assay of VWF in von Willebrand disease and haemophilia: use of a macroscopic platelet aggregation test","volume":"6","author":"Brinkous","year":"1975","journal-title":"Thromb Res"},{"key":"R17-5-20210203","first-page":"152","article-title":"Von Willebrand disease. Laboratory investigation using an improved functional assay for von Willebrand factor","volume":"25","author":"Favarolo","year":"1998","journal-title":"Pathology"},{"issue":"suppl","key":"R18-5-20210203","first-page":"18","article-title":"Dosage de l\u2019antig\u00e8ne li\u00e9 au FVIII par la technique ELISA. Int\u00e9r\u00eat dans l\u2019\u00e9tude de la maladie de Willebrand","volume":"25","author":"Mazurier","year":"1977","journal-title":"Pathol Biol"},{"key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0038-1651565","article-title":"A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate","volume":"69","author":"Peerlynck","year":"1993","journal-title":"Thromb Haemost"},{"key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1055\/s-0038-1649728","article-title":"Inhibitor development and activated factor VIII in concentrates","volume":"70","author":"Barrowcliffe","year":"1993","journal-title":"Thromb Haemost"},{"key":"R21-5-20210203","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0006-291X(92)91769-M","article-title":"Comparison of the primary structure of the functional domains of human and porcine von Willebrand factor that mediate platelet adhesion","volume":"182","author":"Bahnak","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1006\/bbrc.1993.1923","article-title":"Primary structure of the factor VIII binding domain of human porcine and rabbit von Willebrand factor","volume":"194","author":"Lavergne","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"R23-5-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0300-483X(00)00410-8","article-title":"Immunogenicity of biopharmaceuticals in laboratory animals","volume":"158","author":"Wierda","year":"2001","journal-title":"Toxicology"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mbc.0000164427.13417.06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:46:21Z","timestamp":1785851181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-200504000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mbc.0000164427.13417.06","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}